HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus
EK Halvas, KW Joseph, LD Brandt… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND HIV-1 viremia that is not suppressed by combination antiretroviral therapy
(ART) is generally attributed to incomplete medication adherence and/or drug resistance …
(ART) is generally attributed to incomplete medication adherence and/or drug resistance …
Synthesis and characterization of long-acting Darunavir prodrugs
Antiretroviral therapy (ART) has improved the quality of life in patients infected with HIV-1.
However, complete viral suppression within anatomical compartments remains unattainable …
However, complete viral suppression within anatomical compartments remains unattainable …
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug–drug interactions
S Khalilieh, HP Feng, EGJ Hulskotte… - Clinical …, 2015 - Springer
Boceprevir is a potent, orally administered ketoamide inhibitor that targets the active site of
the hepatitis C virus (HCV) non-structural (NS) 3 protease. The addition of boceprevir to …
the hepatitis C virus (HCV) non-structural (NS) 3 protease. The addition of boceprevir to …
Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection
A Jafari, H Khalili, M Izadpanah… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: There are several clinical trials and prospective studies which support the use
of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV)-coinfected patients. In this …
of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV)-coinfected patients. In this …
[引用][C] DRUG INTERACTIONS WITH DISCONTINUED HEPATITIS C PROTEASE INHIBITORS
BM US, HCV Squibb's - Vertex, 2014